/
DCF Valuation
Base-case fair value
$28.22
Intrinsic $37.63 · 25% MOS
Current price: $85.96
Base-case summary
Our base-case DCF for Edwards Lifesciences Corp (EW) projects 10 years of free cash flow growth at 2.0% for years 1–5 and 1.0% for years 6–10, anchored to a default 8% growth assumption, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from $1.1B in trailing free cash flow, this produces an intrinsic value of $37.63 per share. A 25% safety margin gives a fair value of $28.22, suggesting the stock is currently 67% overvalued against the $85.96 market price.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
$1.1B
Cash & equivalents
$3.7B
Total debt
$703M
Shares outstanding
581M